Search Results - "Dorca, Joan"

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study by MARTIN, Miguel, RUIZ, Amparo, MUNOZ-MATEU, Montserrat, DORCA RIBUGENT, Joan, LOPEZ-VEGA, José Manuel, JARA, Carlos, ESPINOSA, Enrique, MENDIOLA FERNANDEZ, César, ANDRES, Raquel, RIBELLES, Nuria, PLAZAOLA, Arrate, SANCHEZ-ROVIRA, Pedro, RUIZ BORREGO, Manuel, SALVADOR BOFILL, Javier, CRESPO, Carmen, CARABANTES, Francisco J, SERVITJA, Sonia, IGNACIO CHACON, José, RODRIGUEZ, César A, HERNANDO, Blanca, ALVAREZ, Isabel, CARRASCO, Eva, LLUCH, Ana, BARNADAS, Agustí, GONZALEZ, Sonia, CALVO, Lourdes, MARGELI VILA, Mireia, ANTON, Antonio, RODRIGUEZ-LESCURE, Alvaro, SEGUI-PALMER, Miguel Angel

“…Adding taxanes to anthracycline-based adjuvant therapy improves survival outcomes of patients with node-positive breast cancer (BC). Currently, however, most…”
Get full text

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study by Pernas, Sonia, Villagrasa, Patricia, Vivancos, Ana, Scaltriti, Maurizio, Rodón, Jordi, Burgués, Octavio, Nuciforo, Paolo, Canes, Jordi, Paré, Laia, Dueñas, Marta, Vidal, Maria, Cejalvo, Juan Miguel, Perelló, Antonia, Llommbard-Cussac, Antonio, Dorca, Joan, Montaño, Alvaro, Pascual, Tomás, Oliveira, Mafalda, Ribas, Gloria, Rapado, Inmaculada, Prat, Aleix, Ciruelos, Eva

“…The SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of…”
Get full text

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin by Cuyàs, Elisabet, Buxó, Maria, Ferri Iglesias, Maria José, Verdura, Sara, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A, Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Joven, Jorge, Brunet, Joan, López-Bonet, Eugeni, Garcia, Margarita, Saidani, Samiha, Queralt Moles, Xavier, Martin-Castillo, Begoña, Menendez, Javier A

“…The minor allele ( ) of the single-nucleotide polymorphism (SNP) , located near the ( ) gene, has been associated with an increased likelihood of treatment…”
Get full text

Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study by APARICIO, Forge, GERMA, José R, BASTUS, Roma, CARIES, Joan, ALMENAR, Daniel, SDNCHEZ, Miguel, PAZ-ARES, Luis, SATRUSTEGUI, Juan J, MELLADO, Begona, BALIL, Ana, LOPEZ-BREA, Marta, SANCHEZ, Alfredo, GARCIA DEL MURO, Xavier, MAROTO, Pablo, ARRANZ, José A, SAENZ, Alberto, BARNADAS, Agustin, DORCA, Joan, GUMA, Josep, OLMOS, David

“…To assess the efficacy of a risk-adapted treatment policy for patients with stage I seminoma by using universally accepted risk criteria. Between 1999 and…”
Get full text

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer by Martin-Castillo, Begoña, Lopez-Bonet, Eugeni, Buxó, Maria, Dorca, Joan, Tuca-Rodríguez, Francesc, Ruano, Miguel Alonso, Colomer, Ramon, Menendez, Javier A

“…There is an urgent need to refine the prognostic taxonomy of HER2+ breast carcinomas and develop easy-to-use, clinic-based prediction algorithms to distinguish…”
Get full text

Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts by Cufi, Silvia, Corominas-Faja, Bruna, Vazquez-Martin, Alejandro, Oliveras-Ferraros, Christina, Dorca, Joan, Bosch-Barrera, Joaquim, Martin-Castillo, Begoña, Menendez, Javier A

“…Trastuzumab-refractory breast cancer stem cells (CSCs) could also explain the high rate of primary resistance to single-agent trastuzumab in HER2…”
Get full text

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study by Martin-Castillo, Begoña, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A, Amillano, Kepa, Domínguez, Severina, Luque, Maria, Stradella, Agostina, Morilla, Idoia, Viñas, Gemma, Cortés, Javier, Cuyàs, Elisabet, Verdura, Sara, Fernández-Ochoa, Álvaro, Fernández-Arroyo, Salvador, Segura-Carretero, Antonio, Joven, Jorge, Pérez, Elsa, Bosch, Neus, Garcia, Margarita, López-Bonet, Eugeni, Saidani, Samiha, Buxó, Maria, Menendez, Javier A

“…The METTEN study assessed the efficacy, tolerability, and safety of adding metformin to neoadjuvant chemotherapy plus trastuzumab in early HER2-positive breast…”
Get full text

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas by Martin-Castillo, Begoña, Lopez-Bonet, Eugeni, Cuyàs, Elisabet, Viñas, Gemma, Pernas, Sonia, Dorca, Joan, Menendez, Javier A

“…Clinically HER2+ (cHER2+) breast cancer (BC) can no longer be considered a single BC disease entity in terms of trastuzumab responsiveness. Here we propose a…”
Get full text

Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients by Cuyàs, Elisabet, Fernández-Arroyo, Salvador, Buxó, Maria, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A, Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Verdura, Sara, Brunet, Joan, López-Bonet, Eugeni, Garcia, Margarita, Saidani, Samiha, Joven, Jorge, Martin-Castillo, Begoña, Menendez, Javier A

“…Certain dietary interventions might improve the therapeutic index of cancer treatments. An alternative to the "drug plus diet" approach is the pharmacological…”
Get full text

Abstract CT154: Multicenter open-label, phase II trial, to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastases in patients with HER2-negative breast cancer (The Phenomenal Study) by Cortés, Javier, Paez, David, García, José Manuel Pérez, Tormo, Salvador Blanch, Parraga, Kepa Amillano, Borrego, Manuel Ruiz, Torres, Antonio Antón, Fernández, María, Conejo, Emilio Alba, Palmer, Miguel Ángel Seguí, Ribugent, Joan Dorca, López López, Rafael, Vila, Mireia Margelí, Aguirre, Elena, Llombart, Antonio

“…Background: HER2-negative metastatic breast cancer (MBC) patients with central nervous system (CNS) involvement previously treated with a local therapy had…”
Get full text

Fatty acid synthase expression is strongly related to menopause in early-stage breast cancer patients by Porta, Rut, Blancafort, Adriana, Casòliva, Gemma, Casas, Miquel, Dorca, Joan, Buxo, Maria, Viñas, Gemma, Oliveras, Glòria, Puig, Teresa

“…OBJECTIVEOverexpression of fatty acid synthase (FASN), the enzyme involved in the de novo synthesis of fatty acids, has been reported in several human…”
Get full text

Stratification of cancer and diabetes based on circulating levels of formate and glucose by Pietzke, Matthias, Arroyo, Salvador Fernandez, Sumpton, David, Mackay, Gillian M, Martin-Castillo, Begoña, Camps, Jordi, Joven, Jorge, Menendez, Javier A, Vazquez, Alexei

“…Serum and urine metabolites have been investigated for their use as cancer biomarkers. The specificity of candidate metabolites can be limited by the impact of…”
Get full text

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin by Cufí, Sílvia, Corominas-Faja, Bruna, Lopez-Bonet, Eugeni, Bonavia, Rosa, Pernas, Sonia, López, Isabel Álvarez, Dorca, Joan, Martínez, Susana, López, Norberto Batista, Fernández, Severina Domínguez, Cuyàs, Elisabet, Visa, Joana, Rodríguez-Gallego, Esther, Quirantes-Piné, Rosa, Segura-Carretero, Antonio, Joven, Jorge, Martin-Castillo, Begoña, Menendez, Javier A

“…Cancer cells expressing constitutively active phosphatidylinositol-3 kinase (PI3K) are proliferative regardless of the absence of insulin, and they form…”
Get full text

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer by Lopez-Bonet, Eugeni, Buxó, Maria, Cuyàs, Elisabet, Pernas, Sonia, Dorca, Joan, Álvarez, Isabel, Martínez, Susana, Pérez-Garcia, Jose Manuel, Batista-López, Norberto, Rodríguez-Sánchez, César A, Amillano, Kepa, Domínguez, Severina, Luque, Maria, Morilla, Idoia, Stradella, Agostina, Viñas, Gemma, Cortés, Javier, Oliveras, Gloria, Meléndez, Cristina, Castillo, Laura, Verdura, Sara, Brunet, Joan, Joven, Jorge, Garcia, Margarita, Saidani, Samiha, Martin-Castillo, Begoña, Menendez, Javier A

“…The proliferative capacity of residual breast cancer (BC) disease indicates the existence of partial treatment resistance and higher probability of tumor…”
Get full text

Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel by Rojo, Federico, Lluch, Ana, Ruiz, Amparo, Ruiz-Borrego, Manuel, Barnadas, Agusti, Calvo, Lourdes, Gonzalez, Sonia, Margeli, Mireia, Rodriguez-Lescure, Alvaro, Anton, Antonio, Seguí, Miguel Angel, Munoz-Mateu, Montserrat, Dorca, Joan, Lopez-Vega, Jose Manuel, Jara-Sanchez, Carlos, Martin, Nuria, Casas, Maribel, Carrasco, Eva Maria, Caballero, Rosalia, Martin, Miguel

“…Abstract only…”
Get full text

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma by Aparicio, J., García del Muro, X., Maroto, P., Paz-Ares, L., Alba, E., Sáenz, A., Terrasa, J., Barnadas, A., Almenar, D., Arranz, J. A., Sánchez, M., Fernández, A., Sastre, J., Carles, J., Dorca, J., Gumà, J., Yuste, A. L., Germà, J. R.

“…Background: After decades of irradiation as standard therapy for clinical stage I testicular seminoma, alternative treatment approaches have emerged including…”
Get full text

First safety results of an international phase II study evaluating oral vinorelbine as a single agent as first-line chemotherapy for metastatic breast cancer patients with bone metastases (NorBreast-228 trial) by Steger, Guenther G., Dobrovolskaya, Natalya, Dominguez, Adriana, Switsers, Odile, Giotta, Francesco, Glogowska, Iwona, Tubiana-Mathieu, Nicole, Pecherstorfer, Martin, Ardizzoia, Andrea, Bougnoux, Philippe, Blasinska-Morawiec, Maria, Veyret, Corinne, Garcia, Sheyla, Dorca Ribugent, Joan, Marth, Christian, Manikhas, Alexey, Benasso, Marco, Protsenko, Svetlana, Villanova, Gustavo, Espinosa, Enrique

“…Abstract only…”
Get full text

Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial by Martin, Miguel, Lluch, Ana, Ruiz, Amparo, Ruiz Borrego, Manuel, Barnadas, Agust, Gonzalez, Sonia, Calvo, Lourdes, Margeli Vila, Mireia, Anton, Antonio, Rodriguez-Lescure, Alvaro, Seguí-Palmer, Miguel Angel, Munoz-Mateu, Montserrat, Dorca Ribugent, Joan, Lopez-Vega, Jose Manuel, Mendiola Fernandez, Cesar, Andres, Raquel, Plazaola, Arrate, Rodriguez, Cesar, Casas, Maria Isabel, Carrasco, Eva Maria

“…Abstract only 1001 Background: Adjuvant weekly paclitaxel (wP) sequential to anthracyclines improves the outcome of operable node-positive BC patients (pts)…”
Get full text

Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung by Fuentes, Rafael, Dorca, Joan, Canals, Eugeni, Izquierdo, Angel, Beltrán, Miguel, Viladiu, Pau

“…A total of 18 patients with locally advanced (Stage III) adenocarcinoma and large cell undifferentiated carcinoma of the lung, previously untreated, were…”
Get full text